ANTIVIRAL DRUGS MARKET ANALYSIS

Regional Analysis

To learn more about this report, Request sample copy

North America remains the dominant region in the global antiviral drugs market is estimated to hold 39.2% of the market share in 2024. With a robust healthcare infrastructure and high healthcare expenditure, the U.S. market alone contributes to over 40% of revenues. Presence of major pharmaceutical companies and strong R&D capabilities have enabled North America to introduce new and innovative drug formulations at regular intervals. This has allowed companies to gain sizeable market shares and establish their market leadership positions within the region over the years. Additionally, favorable regulatory environment and faster approval timelines for new drugs provide an edge to companies operating out of this region.

However, the Asia Pacific region is emerging as the fastest growing market for antiviral drugs. Factors such as improving healthcare infrastructure, rising affordability among consumers, and increasing awareness about treatment of viral infections are driving the growth. Countries like India, China and Japan are at the forefront and contributing significantly to the overall region's revenues. For instance, India's large population base accompanied with rising income levels is benefitting pharmaceutical companies to gain higher volumes sales. Meanwhile, China is utilizing its large talent pool and low-cost advantage to produce affordable generic drugs for both domestic consumption as well as exports to other Asian markets. This is gradually increasing the Asia Pacific region's importance in the global supply chain network.